On the treatment of diabetes mellitus with glucagon-like peptide-1

Annals of the New York Academy of Sciences

Volumn 865, Issue , 1998, Pages 336-343

  Holst, Jens Juul ^a   Deacon, Carolyn ^a   Toft Nielsen, Maj Brit ^b   Bjerre Knudsen, Lotte ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE;

CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG STABILITY; ENZYME INHIBITION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTEIN SECRETION; SATIETY; SUBCUTANEOUS DRUG ADMINISTRATION; TABLET;

EID: 0032419579     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb11193.x     Document Type: Conference Paper

References (37)

1. Holst, J. J., M. B. Toft-Nielsen, C. Ørskov, M. Nauck & B. Willms. 1996. On the effects of glucagonlike peptidel on blood glucose regulation in normal and diabetic subjects. Ann. N. Y. Acad. Sci. 805: 729-736.
2. Gutniak, M., C. Ørskov, J. J. Holst, B. Ahren & S. Efendic. 1992. Antidiabetogenic effect of glucagonlike peptide-1(7-36)amide in normal subjects and patients with diabetes mellitus [see comments]. N. Engl. J. Med. 326: 1316-1322.
3. Nauck, M. A., N. Kleine, C. Ørskov, J. J. Holst, B. Willms & W. Creutzfeldt. 1993. Normalization of fasting hyperglycaemia by exogenous glucagonlike peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744.
4. Larsen, J., N. Jallad & P. Damsbo. 1996. One-week continuous infusion of GLP-1(7-37) improves glycemic control in NIDDM. Diabetes 45(suppl 2): 233A.
5. Rachman, J. & R. C. Turner. 1995. Drugs on the horizon for treatment of type 2 diabetes. Diabetic Med. 12: 467-478.
6. Holst, J. J. 1997. Enteroglucagon. Annu. Rev. Physiol. 59: 257-271.
7. Wettergren, A., B. Schjoldager, P. E. Mortensen, J. Myhre, J. Christiansen & J. J. Holst. 1993. Truncated GLP-1 (proglucagon 72-107amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 38: 665-673.
8. Nauck, M. A., U. Niedereichholz, R. Ettler, J. J. Holst, C. Ørskov, R. Ritzelt & W. H. Schmiegel. 1997. The glucagon-like peptide-1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 273: E981-E988.
9. Scrocchi, L. A., T. J. Brown, N. Maclusky, P. L. Brubaker, A. B. Auerbach, A. L. Joyner & D. J. Drucker. 1996. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 2: 1254-1258.
10. Flint, A., A. Raben, A. Astrup & J. J. Holst. 1998. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101: 515-520.
11. Turton, M. D., D. O'Shea, I. Gunn, S. A. Beak, C. M. Edwards, K. Meeran, S. J. Choi, G. M. Taylor, M. M. Heath, P. D. Lambert, J. P. Wilding, D. M. Smith, M. A. Ghatei, J. Herbert & S. R. Bloom. 1996. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72.
12. Tang Christensen, M., P. J. Larsen, R. Goke, A. Fink Jensen, D. S. Jessop, M. Moller & S. P. Sheikh. 1996. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am. J. Physiol. 271: R848-56.
13. Larsen, P. J., M. Tang Christensen, J. J. Holst & C. Ørskov. 1997. Distribution of glucagon- like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem. Neuroscience 77: 257-270.
14. Ørskov, C., S. S. Poulsen, M. Moller & J. J. Holst. 1996. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45: 832-835.
15. Wei, Y. & S. Mojsov. 1995. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 358: 219-224.
16. Willims, B., J. Werner, J. J. Holst, C. Ørskov, W. Creutzfeldt & M. A. Nauck. 1996. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-I (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J. Clin. Endocrinol. Metab. 81: 327-332.
17. Ritzel, R., C. Ørskov, J. J. Holst & M. A. Nauck. 1995. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38: 720-725.
18. Ørskov, C., A. Wettergren & J. J. Holst. 1993. The metabolic rate and the biological effects of GLP-1 7-36amide and GLP-1 7-37 in healthy volunteers are identical. Diabetes 42: 658-661.
19. Deacon, C. F., L. Pridal, L. Klarskov, M. Olesen & J. J. Holst. 1996. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am. J. Physiol. 271: E458-64.
20. Deacon, C. F., A. H. Johnsen & J. J. Holst. 1995. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80: 952-957.
21. Knudsen, L. B. & L. Pridal. 1996. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. 318: 429-435.
22. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131.
23. Holst, J. J., L. Hansen & C. F. Deacon. 1997. The GLP-1 receptor antagonist, GLP-1 (9- 36amide), is a primary product of the intestinal L-cell. Diabetologia 40 (suppl.1): A27.
24. Nauck, M. A., D. Wollschlager, J. Werner, J. J. Holst, C. Ørskov, W. Creutzfeldt & B. Willms. 1996. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39: 1546-1553.
25. Mentlein, R., B. Gallwitz & W. E. Schmidt. 1993. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214: 829-835.
26. Deacon, C. F., L. Bjerre Knudsen, N. L. Johansen, K. Madsen & J. J. Holst. 1997. Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1: in vitro and in vivo studies. Diabetologia 40 (suppl 1): A127.
27. Pederson, R. A., T. J. Kieffer, R. Pauly, H. Kofod, J. Kwong & C. H. S. McIntosh. 1996. The enteroinsular axis in dipeptidyl peptidase IV-negative rats. Metabolism 45: 1335-1341.
28. Deacon, C. F., L. Pridal, M. Olesen, L. Klarskov & J. J. Holst. 1996. Dipeptidyl peptidase IV inhibition influences GLP-1 metabolism in vivo. Regul. Pept. 64: 30.
29. Deacon, C. F., T. E. Hughes & J. I. Holst. 1998. Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide-1 in the anaesthetized pig. Diabetes 47: 764-769.
30. Qualmann, C., M. A. Nauck, J. J. Holst, C. Ørskov & W. Creutzfeldt. 1995. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand. J. Gastroenterol. 30: 892-896.
31. Seifarth, C., J. Bergmann, J. J. Holst, R. Ritzelt, W. Schmiegel & M. A. Nauck. 1997. Influence of acarbose on GLP-1 release after a sucrose load in NIDDM patients. Diabetologia 40(suppl. 1): A131.
32. Gutniak, M. K., H. Larsson, S. J. Heiber, O. T. Juneskans, J. J. Holst & B. Ahrkn. 1996. Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 19: 843-848.
33. Gutniak, M. K., H. Larsson, S. W. Sanders, O. Juneskans, J. J. Holst & B. Ahrén. 1997. GLP-1 tablet in NIDDM in fasting and postprandial conditions. Diabetes Care 20: 1874-1879.
34. Pridal, L., H. Agerbæk, L. N. Christensen, K. Thomsen & O. Kirk. 1996. Absorption of glucagon-like peptidc-1 can be protracted by zinc or protamine. Int. J. Pharm. 136: 53-59.
35. Adelhorst, K., B. B. Hedegaard, L. B. Knudsen & O. Kirk. 1994. Structure-activity studies of glucagon-like peptide-1. J. Biol. Chem. 269: 6275-6278.
36. Hjorth, S. A., K. Adelhorst, B. B. Pedersen, O. Kirk & T. W. Schwartz. 1994. Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. J. Biol. Chem. 269: 30121-30124.
37. Finn, P. W. 1996. Computer-based screening of compound databases for the identification of novel leads. Drug Discovery Today 1: 363-370.